Dr. Lal Path Labs Ltd. has informed the Exchange about Investor Presentation
LALPATHLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Dr. Lal PathLabs reported Q1 FY26 revenue of Rs. 670 crore, up 11.3% year-on-year, driven by 10.7% growth in sample volumes to 23.4 million and 5.3% growth in patient count to 7.6 million. EBITDA rose 13.1% to Rs. 192 crore with margins improving to 28.7% (from 28.2%), helped by better mix, network expansion and cost efficiencies. Profit after tax jumped 24.3% to Rs. 134 crore, with PAT margins expanding sharply to 20.0% (from 17.9%) and EPS rising 24.4% to Rs. 15.9. The company highlighted its calibrated expansion into Tier 3 and Tier 4 cities, the integration of Suburban Diagnostics boosting West India, and SwasthFit contributing 27% of revenue. The network stands at 298 labs, 6,607 patient service centres and 12,365 pick-up points, with Rs. 1,229 crore in cash and a net cash balance sheet.
Strong volume-led growth with notable margin expansion signals healthy operating leverage and reinforces the company's pricing power. The combination of robust cash generation, zero debt and continued network expansion is positive for shareholders and likely to support the stock in the near term.